Home The Word Brain My Amedeo FAQ Privacy About   


Chinese Coaching

Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.


  Prostate Cancer

  Free Subscription


12.01.2026

1 AJR Am J Roentgenol
5 BJU Int
3 BMC Cancer
1 Br J Cancer
1 Br J Radiol
1 Cancer Lett
1 Eur Urol
1 Hum Pathol
1 Int J Cancer
1 Int J Urol
1 J Nucl Med
1 Magn Reson Med
1 Oncogene
2 PLoS One
4 Prostate


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. GELIKMAN DG, Yilmaz EC, Harmon SA, Huang EP, et al
    Evaluating Artificial Intelligence-Assisted Prostate Biparametric MRI Interpretation: An International Multireader Study.
    AJR Am J Roentgenol. 2025 Jul 16. doi: 10.2214/AJR.24.32399.
    PubMed         Abstract available


    BJU Int

  2. YOUNG GJ, Walsh EI, Lane JA, Donovan JL, et al
    Patient-reported outcome measures in prostate research: a scoping review.
    BJU Int. 2026;137:241-250.
    PubMed         Abstract available

  3. SHIRAFUJI T, Yamada Y, Sato K, Xue Z, et al
    Discordance between PSA level and bone metastatic volume is associated with unfavourable prognosis.
    BJU Int. 2026;137:368-375.
    PubMed         Abstract available

  4. NUNES P, Richaud F, Quantin C, Binquet C, et al
    Comparison of short-term complications after open, laparoscopic and robot-assisted radical prostatectomy.
    BJU Int. 2026;137:348-359.
    PubMed         Abstract available

  5. SANDHU K, Wells C, Lawrentschuk N
    Emerging radiotracers in prostate cancer: opportunities and challenges.
    BJU Int. 2026 Jan 4. doi: 10.1111/bju.70132.
    PubMed        

  6. SEMWAL BC, Yadav S, Gupta PS
    Comment on 'Prostate zonal impact of 5alpha-reductase inhibitors on multiparametric MRI characteristics and detection of prostate cancer'.
    BJU Int. 2026 Jan 8. doi: 10.1111/bju.70138.
    PubMed        


    BMC Cancer

  7. MATSUDA K, Ogata T, Kamitani N, Watanabe K, et al
    Retrospective analysis of high-dose-rate brachytherapy for patients with prostate cancer aged >/= 75 years.
    BMC Cancer. 2026 Jan 7. doi: 10.1186/s12885-025-15533.
    PubMed        

  8. AYALEW TL, Feleke MG, Ashager K, Eshetu A, et al
    Prostate cancer screening and associated factors in Ethiopia: a systematic review and meta-analysis.
    BMC Cancer. 2026 Jan 7. doi: 10.1186/s12885-025-15480.
    PubMed         Abstract available

  9. ALTINOZ HB, Sanlier N
    Green tea catechins and prostate cancer: mechanisms, clinical evidence, and safety: a narrative review.
    BMC Cancer. 2026 Jan 8. doi: 10.1186/s12885-025-15516.
    PubMed         Abstract available


    Br J Cancer

  10. VLACHOS G, Moser T, Lazzeri I, Moser MJ, et al
    Functional footprints of homologous recombination deficiency in prostate cancer revealed by ctDNA fragmentation and transcription factor accessibility.
    Br J Cancer. 2026 Jan 9. doi: 10.1038/s41416-025-03301.
    PubMed         Abstract available


    Br J Radiol

  11. ZHONG J, Che Z, Qin X, Zhang Y, et al
    Zonal origin combined with IVIM parameters could predict ISUP risk groups of prostate cancer.
    Br J Radiol. 2026 Jan 8:tqag002. doi: 10.1093.
    PubMed         Abstract available


    Cancer Lett

  12. ZHANG Y, Zhao H, Xu P, Liu K, et al
    The Zeb1/system X(c)(-) axis safeguards iron-loaded cancer-associated fibroblasts against ferroptosis and promotes immunosuppression in prostate cancer.
    Cancer Lett. 2026;639:218243.
    PubMed         Abstract available


    Eur Urol

  13. GHADJAR P, Hayoz S, Zwahlen DR, Holscher T, et al
    Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial.
    Eur Urol. 2026 Jan 5:S0302-2838(25)04875-4. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available


    Hum Pathol

  14. YU B, Zhou X, Bian F, Yan F, et al
    Long-term outcomes of prostate cancer patients with metastases in the anterior fat pad and pelvic lymph nodes: Nodal upstaging without worse long-term outcomes.
    Hum Pathol. 2026;170:106033.
    PubMed         Abstract available


    Int J Cancer

  15. DAI J, Zhou X
    Comments on "Risk factors for low-risk prostate cancer: A retrospective cohort study within the FinRSPC trial".
    Int J Cancer. 2026 Jan 6. doi: 10.1002/ijc.70306.
    PubMed        


    Int J Urol

  16. TAMADA T, Takeuchi M, Moriya K, Ueda Y, et al
    The Evolution of Prostate Multiparametric MRI and Its Application in Prostate Cancer Clinical Management.
    Int J Urol. 2026 Jan 7. doi: 10.1111/iju.70338.
    PubMed         Abstract available


    J Nucl Med

  17. ABDEL-WAHAB M, Giammarile F
    Nuclear Medicine and External Beam Radiation Therapy in Prostate Cancer: A Synergistic Approach.
    J Nucl Med. 2026 Jan 8:jnumed.125.271268. doi: 10.2967/jnumed.125.271268.
    PubMed         Abstract available


    Magn Reson Med

  18. ZHANG HZ, Elsaid NMH, Nixon TW, Dewdney A, et al
    Strong-Gradient Diffusion-Weighted Imaging of Prostate Cancer Using an Inside-Out Nonlinear Gradient Coil.
    Magn Reson Med. 2026 Jan 8. doi: 10.1002/mrm.70252.
    PubMed         Abstract available


    Oncogene

  19. XIE W, Chu Q, Brea L, Zeng G, et al
    EZH2 PROTACs outperform catalytic inhibitors in prostate cancer by targeting a methylation-independent function of PRC2.
    Oncogene. 2026 Jan 7. doi: 10.1038/s41388-025-03662.
    PubMed         Abstract available


    PLoS One

  20. RAMEZANI SR, Mojra A, Tafazzoli-Shadpour M
    Mechanochemical interactions in cancer cells: The role of substrate stiffness in cell behavior and drug response.
    PLoS One. 2026;21:e0327874.
    PubMed         Abstract available

  21. LEE J, Song M, Leem S, Kim JY, et al
    Correction: Adverse events of androgen receptor pathway inhibitors in prostate cancer from real world data.
    PLoS One. 2026;21:e0340507.
    PubMed         Abstract available


    Prostate


  22. NOTIFICATION: RhoGDIalpha Downregulates Androgen Receptor Signaling in Prostate Cancer Cells.
    Prostate. 2026 Jan 5. doi: 10.1002/pros.70121.
    PubMed         Abstract available

  23. UYAR A, Tasdemir B, Tuzcu SA, Oruc Z, et al
    Role of Volumetric Parameters Derived From Ga-68 PSMA PET-CT in Predicting Treatment Response.
    Prostate. 2026;86:372-376.
    PubMed         Abstract available

  24. DUPUIS R, Fort N, Mousset C, Bruyere F, et al
    Spatial Characteristics of Intraductal Carcinoma of the Prostate.
    Prostate. 2026;86:349-356.
    PubMed         Abstract available


  25. EXPRESSION OF CONCERN: Functional p53 Determines Docetaxel Sensitivity in Prostate Cancer Cells.
    Prostate. 2026 Jan 6. doi: 10.1002/pros.70120.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.